Regarding the primary endpoint, Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day, +1.28% + 0.90%; Ubiquinol 100 mg/day, +1.34% + 1.445%; placebo -0.41% + 1.51%; P<0.001). Response with Ubiquinol was dose-independent. There were no significant changes in plasma lipid profile for any group, and no adverse events were reported.
Ubiquinol also provided significant improvements on 3 secondary endpoints: Ubiquinol increased plasma CoQ10 levels versus placebo (P<0.001), and reduced the percentage of oxidized CoQ10 (P<0.001); serum nitric oxide (NOx) increased significantly in subjects receiving Ubiquinol (P=0.016) versus placebo; and LDL oxidation lag time improved significantly in those receiving 200 mg/day Ubiquinol (P=0.017) versus placebo.
"This is the first evidence of the protective effect of Ubiquinol on endothelial function in healthy adult subjects with mild-to-moderate dyslipidemia," said
"Patients need additional options to improve cardiovascular health. Cardiovascular diseases are a leading cause of death globally," said Dr.
About Ubiquinol
Kaneka Ubiquinol® is one of the strongest lipid-soluble antioxidants available. Kaneka Ubiquinol® provides defense against oxidative damage to the body's cells, including lipids, proteins and DNA. It also plays an essential role in cellular ATP (energy) production.
As the reduced and more bioavailable form of coenzyme Q10 (CoQ10), Kaneka Ubiquinol® has even more of the same powerful benefits associated with Kaneka Q10® that have been well established over the past three decades. Both CoQ10 and Ubiquinol naturally exist in the blood, but the body must convert oxidized CoQ10 into active Ubiquinol before it can play a role in providing cellular energy and act as an antioxidant. The ability to convert oxidized CoQ10 to active Ubiquinol becomes less efficient as a person ages, which is why people over 40 may receive a greater benefit from taking a Ubiquinol supplement versus CoQ10. Kaneka Ubiquinol® has been shown to be up to 70% more bioavailable and better absorbed than conventional CoQ10.
About Kaneka Nutrients
Kaneka Nutrients, a Division of
We proudly manufacture both Kaneka Ubiquinol® and Kaneka Q10® at our plant in
Additional information can be found at: https://www.healthcare/ubiquinol.org.
© 2020 Kaneka Nutrients, a Division of
References
Sabbatinelli J, Orlando P, Galeazzi R. Ubiquinol ameliorates endothelial dysfunction in subjects with mild-to-moderate dyslipidemia: a randomized clinical trial. Nutrients. 2020;12(4):1098. doi: 10.3390/nu12041098.
Thijssen DHJ, Bruno RM, van Mil A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans.
Langsjoen PH, Langsjoen AM. Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone. Clin Pharmacol Drug Dev. 2013;3(1):13-17.
Senior Director of Marketing
Kaneka Nutrients
(281) 291-3185
Ronald.martin@kaneka.com
Source: Kaneka Nutrients
View original content to download multimedia:http://www.prnewswire.com/news-releases/results-evaluating-the-effect-of-ubiquinol-on-endothelial-function-published-in-nutrients-301145789.html
SOURCE Kaneka Nutrients
© Canada Newswire, source